- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01133743
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia
An Open-Label Phase 2 Study of Lenalidomide (Revlimid) in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia (CLL)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- University Health Network - Princess Margaret Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
- Understand and voluntarily sign an informed consent form.
- Age >/=18 years at the time of signing the informed consent form.
- Able to adhere to the study visit schedule and other protocol requirements.
- A confirmed diagnosis of B-cell CLL by IWCLL 2008 criteria
No prior systemic therapy for CLL. Steroid therapy alone for autoimmune cytopenias (anemia or thrombocytopenia) is NOT considered a prior systemic therapy.
Radiation: Patients may have received prior radiation therapy restricted to </= 25% of functioning bone marrow. Patients must be >/= 4 weeks since last treatment with radiation therapy.
Surgery: previous surgery is permissible. Patient must be >/= 4 weeks since any major surgery.
Patients must have symptomatic disease requiring therapy as per the IWCLL 2008 criteria. One or more of the following must be present to be eligible:
- Massive (>10cm diameter), progressive or symptomatic lymphadenopathy
- Massive (>6 cm below costal margin) or progressive or symptomatic splenomegaly
- Anemia (Hb <110 g/L)
- Thrombocytopenia (platelets <100 x 109/L)
- Constitutional symptoms (one of the following):
- Weight loss >10% or more over previous 6 months
- Significant fatigue
- Fevers >38 degrees Celsius for 2 or more weeks without infection
- Night sweats > 1 month without evidence of infection
- Other constitutional symptoms felt to require treatment as per treating physician discretion
- Persistent rise in lymphocyte count with doubling time of < 6 months
- Autoimmune anemia and/or thrombocytopenia poorly responsive to corticosteroids or other standard therapy
- ECOG performance status of </= 2 at study entry
- Laboratory Requirements: (must be done within 7 days prior to first study drug dose) Hematology: Absolute granulocytes (AGC)>/= 1000/mm³ Platelets >/= 50,000/mm³ Chemistry: Creatinine clearance>/= 30ml/min (by Cockcroft-Gault calculation, see Appendix 9) Bilirubin </= 1.5 x UNL AST (or ALT if AST not available) </= 2.5 x UNL
- Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
- Disease free of prior malignancies for >/= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast
- Able to take aspirin 81 mg daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).
Exclusion criteria:
Patients who fulfill any of the following criteria are not eligible for admission to the study:
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
- Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
- Evidence of laboratory TLS by Cairo-Bishop Definition of Tumor Lysis Syndrome. Subjects may be enrolled upon correction of electrolyte abnormalities.
- Use of any other experimental drug or therapy within 28 days of baseline.
- Known hypersensitivity to thalidomide.
- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
- Any prior use of lenalidomide.
- Concurrent use of other anti-cancer agents or treatments.
- Known positive for HIV or infectious hepatitis, type B or C.
- Known intolerance to steroids (i.e. poorly controllable hyperglycemia or hypertension, significant mood disturbances, steroid-related myopathy, etc.)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Lenalidomide and Dexamethasone
Lenalidomide target dose of 25 mg PO OD continuously (28-day cycle) using an initial dose escalation period.
Oral dexamethasone 12 mg daily on days 1-7, 14 and 21 of each cycle.
|
Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle.
Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily.
Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Response rate
Tidsramme: 18 cycles (each cycle is of 28 days)
|
18 cycles (each cycle is of 28 days)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Time to progression
Tidsramme: Participants will be followed until death
|
Participants will be followed until death
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Dr. Christine I Chen, MD, University Health Network, Toronto
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- Leukæmi, B-celle
- Leukæmi
- Leukæmi, lymfatisk, kronisk, B-celle
- Leukæmi, lymfoid
- Lægemidlers fysiologiske virkninger
- Anti-infektionsmidler
- Autonome agenter
- Agenter fra det perifere nervesystem
- Anti-inflammatoriske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Antibakterielle midler
- Leprostatiske midler
- Dexamethason
- Thalidomid
- Lenalidomid
Andre undersøgelses-id-numre
- RV-CLL-PI-0411
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kronisk lymfatisk leukæmi
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Novartis PharmaceuticalsLedigPrimær myelofibrose (PMF) | Polycytæmi Vera (PV) | Post polycytæmi myelofibrose (PPV MF) | Trombocytæmi myelofibrose (PET-MF) | Alvorlig/meget svær COVID-19 sygdom | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)
Kliniske forsøg med Lenalidomide and Dexamethasone
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRekruttering
-
Bristol-Myers SquibbAfsluttetMyelomatoseForenede Stater, Frankrig, Australien
-
Gesellschaft fur Medizinische Innovation - Hamatologie...ClinAssess GmbHAfsluttetMyelomatoseTyskland
-
TJ Biopharma Co., Ltd.Aktiv, ikke rekrutterendeRefraktær Myelom | Myelom i tilbagefaldKina, Taiwan
-
Celgene CorporationAfsluttetDiffust storcellet B-celle lymfomForenede Stater, Canada, Australien
-
University of LeedsTakeda; Cancer Research UK; CelgeneRekrutteringMyelomatoseDet Forenede Kongerige
-
University Health Network, TorontoAfsluttetMyelomatose | NyresvigtCanada
-
Celgene CorporationAfsluttetKolorektal cancerAustralien, Belgien, Tyskland, Italien, Spanien, Sverige
-
Mayo ClinicNational Cancer Institute (NCI)AfsluttetMyelom og plasmacelle-neoplasmaForenede Stater
-
Samsung Medical CenterAktiv, ikke rekrutterendeMyelomatoseKorea, Republikken